doctors in training

Houston medical school presents inaugural class as construction begins on new building

The University of Houston broke ground on its new medical school building and named the College of Medicine's inaugural class. Photo via UH.edu

This month, the University of Houston has taken a couple huge steps toward establishing a prestigious medical school program — the first new medical school to be established in Houston in almost 50 years.

UH has broken ground on its $80 million medical school building that is expected to be completed in 2022, and the program has named its inaugural class.

The new cohort of future doctors is a group diverse in ethnic background and life experience. The school plans to tackle a key issue in public health: the shortage of primary care doctors. These future doctors are charged by the university with eliminating health disparities in underserved urban and rural areas, which often have poorer health outcomes.

The UH College of Medicine received 1,728 applications for its first class of students; 164 applicants were interviewed for the 30 available spots, according to UH. An 18-member admissions committee screened those most likely to pursue primary care.

Here is a breakdown of UH's inaugural medical school class:

  • 30 students
  • 73 percent underrepresented minorities in medicine
  • 63 percent female
  • 57 percent first generation in college
  • 40 percent low socioeconomic status
  • 100 percent Texas resident
  • Five graduates of the University of Texas at Austin; two graduates each from the University of Houston, Baylor, Texas A&M, Houston Baptist, Prairie View A&M, and Rice University

According to the school, the goal is for 50 percent of graduates of the UH College of Medicine to choose primary care specialties including family medicine, general internal medicine, and general pediatrics. For some perspective, nationally, only about 20 percent of medical students choose primary care.

"We were very deliberate in our pursuit of medical students who fit the mission. This is much different than most other medical schools because we need different solutions for the current health care problems facing our city and state," said Dr. Stephen Spann, founding dean of the College of Medicine, in a statement.

Each student will receive a $100,000 four-year scholarship through philanthropy to cover tuition and fees. At full enrollment, the College of Medicine will have 480 students, per the school. The Health 2 Building in the UH Medical District will be the college's temporary home for the first two years until a new $80 million medical school building is completed in 2022. Construction crews broke ground on the new building on June 15, according to the university.

Being part of UH's inaugural medical school is deeply personal for students such as Cenk Cengiz. At 14, Cengiz's family emigrated from Turkey to Houston, but could not afford health insurance. Cengiz attended high school and college without ever seeing a doctor, which attracted him to the field of medicine and peaked his interest in the medical school's unique mission to help underserved communities.

"I came a long way from washing dishes at age 14 at a pizza store," Cengiz said in a statement. "My parents are super proud of me."

Dr. Stephen Spann is the founding dean of the College of Medicine. Photo via uh.edu

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted